Notícias e Destaques The Myeloma Matrix Part II (Preclinical -> Phase I/II)

The Myeloma Matrix Part II (Phase I -> Phase I/II)
3.21.06

The IMF is committed to providing a total overview of the "future" as well as the current state of myeloma treatments. The printed version of the Myeloma Matrix provides updated information about drugs beginning with pre-clinical developments, tracks drugs as they proceed through Phases I – III of clinical trials, and provides information on trials that are being conducted by NCI-sponsored cooperative groups as well as other myeloma study groups. Call the toll-free hotline (800) 452-2873 for your printed copy.

  • Pre-clinical—Testing of new therapies in a laboratory setting prior to testing on human subjects.
  • Phase I—Assess side effects of the treatment and determine a maximum tolerated dose.
  • Phase II—Assess anti-myeloma effects of treatment at the dose established in Phase I trial.
  • Phase III—Compare a newer treatment against current standard treatment.

To The Myeloma Matrix Part III (Pre-clinical) >>

PHASE

BRAND NAME
(OTHER NAME)

COMPANY
(SPONSOR)

INDICATION

Phase I/II

Actimid™
(CC-4047)

Celgene Corporation

Immunomodulatory agent for relapsed/refractory myeloma. Trials only in UK.

Amplimexon
(imexon)

AmpliMed Corp.

Rapamycin analog administered IV.

Atiprimod

Calisto
Pharmaceuticals

For patients with refractory multiple myeloma who have failed two or more prior therapies.

AVN944

Avalon Pharmaceuticals

Open-label, repeat-dose escalation, safety and tolerability trial for patients with advanced hematological malignancies.

BrevaRex®

AltaRex

Trials planned for monoclonal antibody against MUC1 antigen.

Brostallicin
(PNU-166196)

Pharmacia and NCI

For the treatment of recurrent or refractory multiple myeloma.

CERA
(Continuous
Erythropoiesis
Receptor
Activator)

Roche

Indication: treatment of cancer-related anemia

CNTO 328

Centocor

Monoclonal antibody to IL-6

Curcumin
(diferuloyl-
methane)

MD Anderson CC

Present in turmeric and yellow mustard, inhibits NF-kappaB.

Defibrotide

Gentium S.p.A.

Used as a MM cell sensitizer in combination with melphalan, prednisone, thalidomide as salvage treatment in advanced myeloma.

GCS-100LE

GlycoGenesys, Inc.

Dose-escalation study of polysaccharide-based (carbohydrate) agent for relapsed/refractory myeloma.

Idiotypic
vaccination
+ miniallo-
transplant

University Clinic of Navarre
Pamplona, Spain

Patients (either newly-diagnosed or in partial response following autologous transplantation) with HLA full-matched, sibling donor.

Quadramet
(samarium
Sm-153
lexidronam)

Cytogen Corporation

For the treatment of bone pain associated with metastatic bone disease in patients with recurrent or refractory myeloma.

Stemgen

Amgen

Tested abroad as stem cell booster; protocols pending in US.

TacI-Ig

ZymoGenetics

Fusion protein given to patients with relapsed/refractory myeloma

Trisenox™
(arsenic
trioxide
injection)

Cell Therapeutics, Inc.

With vitamin C for relapsed and refractory multiple myeloma.

VELCADE®
(bortezomib,
PS-341,
LDP-341,
MLN-341)

Millennium Pharmaceuticals

With Adriamycin and dex as front-line therapy. (UK only)

VELCADE®
(bortezomib,
PS-341,
LDP-341,
MLN-341)

Millennium Pharmaceuticals

As maintenance therapy after auto-transplant in patients with intermediate or advanced MM.

VQD-001
(sodium stibogluconate, SSG)

VioQuest Pharmaceuticals, Inc.

Targeted to protein tyrosine phosphatases; safety, efficacy, and tolerability trial for solid tumors, lymphoma, and myeloma.

ZIO-101

ZIOPHARM, Inc.

Multi-center trial of small-molecule organic arsenic

Phase I

1D09C3

GPC Biotech

Anti-major histocompatibility complex (MHC) class II monclonal antibody that has received orphan medicinal product designation for the treatment of myeloma by the European Medicines Agency.

17-AAG
(KOS-953;
17-allylamino-
17-demethoxy-
geldanamycin)

Kosan Biosciences

Inhibitor of heat shock protein 90 being evaluated both as monotherapy and in combination with VELCADE for patients with relapsed, refractory multiple myeloma.

Allomune System

BioTransplant

To facilitate acceptance of donor stem cells.

anti-IGF-1R
mAb
(CP-571,871);
monoclonal
antibody to
insulin-like
growth factor
-1 receptor)

Pfizer

Relapsed and refractory MM.